{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:59:36Z","timestamp":1792699176173,"version":"4.5.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p><jats:bold>Objectives:<\/jats:bold> The aim of this systematic review is to assess the published cost-effectiveness analyses of aprepitant for patients with chemotherapy-induced nausea and vomiting (CINV).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A systematic literature search was performed on PubMed, EMbase, the Cochrane Library, CNKI, WANFANG DATA, and CBM database. The date of publication is up to January 2019. Two reviewers independently reviewed titles, abstracts, and articles sequentially to select studies for data abstraction based on the inclusion and exclusion criteria. Disagreements were resolved and reviewers reached a consensus. The quality of the included studies was assessed according to the 24-item checklist of the consolidated health economic evaluation reporting standards (CHEERS). The costs reported by the included studies were converted to US dollars <jats:italic>via<\/jats:italic> purchasing power parities (PPP) in the year 2019 using the CCEMG\u2013EPPI\u2013Certer Cost Converter.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Thirteen articles were included based on the inclusion criteria for cost-effectiveness analysis and cost-utility analysis. Twelve studies were rated as good quality and one as a moderate quality based on the CHEERS checklist. Eight studies compared aprepitant plus 5-hydroxytryptamine-3 receptor antagonist (5-HT3RA) and dexamethasone with the standard regimen (5-HT3RA and dexamethasone). It was concluded that aprepitant plus standard regimen was a cost-effective strategy for preventing CINV. Only one study that compared aprepitant plus 5-HT3RA with 5-HT3RA, concluded that the addition of aprepitant reduced the incidence of severe nausea, and it might also provide an economic benefit in the overall management. Four studies that compared aprepitant with other antiemetic drugs concluded that aprepitant is a cost-effective strategy for preventing CINV compared with metoclopramide. However, netupitan + palonosetron and olanzapine are cost-effective compared with aprepitant.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> This study is the first systematic evaluation of adding aprepitant to standard regimens for patients with CINV. Most economic evaluations of antiemetic medications are reported to be of good quality. Adding aprepitant to standard regimens is found to be a cost-effective strategy for preventing CINV.<\/jats:p>","DOI":"10.3389\/fpubh.2021.660514","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T09:15:01Z","timestamp":1629882901000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Cost-Effectiveness of Aprepitant in Preventing Chemotherapy-Induced Nausea and Vomiting: A Systematic Review of Published Articles"],"prefix":"10.3389","volume":"9","author":[{"given":"Tingting","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Men","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suodi","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,25]]},"reference":[{"key":"B1","first-page":"637","article-title":"Practical management of chemotherapy-induced nausea and vomiting","volume":"19","author":"Wiser","year":"2005","journal-title":"Oncology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40265-013-0019-1","article-title":"Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents","volume":"73","author":"Navari","year":"2013","journal-title":"Drugs."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","article-title":"The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin\u2014The Aprepitant Protocol 052 Study Group","volume":"21","author":"Hesketh","year":"2003","journal-title":"J Clin Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1002\/cncr.11433","article-title":"Addition of neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting, results from a randomized, double-blind, placebo-controlled trial in Latin America","volume":"97","author":"Poli-Bigelli","year":"2003","journal-title":"Cancer."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/annonc\/mdl019","article-title":"Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment","volume":"17","author":"Schmoll","year":"2006","journal-title":"Ann Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1200\/JCO.2005.09.050","article-title":"Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy","volume":"23","author":"Warr","year":"2005","journal-title":"J Clin Oncol."},{"key":"B7","unstructured":"EttingerDS\n            BergerMJ\n            AshtonJ\n            BarbourS\n            BergsbakenJ\n            BrandtD\n          Antiemetics NCCN Clinical Practice Guidelines in Oncology Version1.2021[EB\/OL]. National Comprehensive Cancer Network: Antiemesis 2021 v12020"},{"key":"B8","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1200\/JCO.2015.64.3635","article-title":"Antiemetics: American Society Of Clinical Oncology Focused Guideline Update","volume":"34","author":"Hesketh","year":"2016","journal-title":"J Clin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Ann Oncol"},{"key":"B10","first-page":"263","article-title":"Tumor treatment related vomiting prevention guide (2014 edition)","volume":"19","author":"Yu","year":"2014","journal-title":"Chinese Clin Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1002\/cncr.27899","article-title":"Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer: a populationbased study","volume":"119","author":"Gomez","year":"2013","journal-title":"Cancer."},{"key":"B12","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg."},{"key":"B13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS)\u2014explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health."},{"key":"B14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s40273-013-0032-y","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement","volume":"31","author":"Husereau","year":"2013","journal-title":"Pharmacoeconomics."},{"key":"B15","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1136\/oemed-2012-100668","article-title":"Worksite mental health interventions: a systematic review of economic evaluations","volume":"69","author":"Hamberg-van Reenen","year":"2012","journal-title":"Occup Environ Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/eip.12156","article-title":"Economic evaluations of interventions designed to prevent mental disorders: a systematic review","volume":"9","author":"Mihalopoulos","year":"2015","journal-title":"Early Interv Psychiatry."},{"key":"B17","unstructured":"Prices and Purchasing Power Parities (PPP): PPs and Exchange Rates2019"},{"key":"B18","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00520-007-0349-1","article-title":"Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium","volume":"16","author":"Annemans","year":"2008","journal-title":"Support Care Cancer."},{"key":"B19","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.suponc.2010.09.027","article-title":"Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients","volume":"8","author":"Avritscher","year":"2010","journal-title":"J Support Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"212298","DOI":"10.7573\/dic.212298","article-title":"NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK","volume":"6","author":"Cawston","year":"2017","journal-title":"Drugs Context."},{"key":"B21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/ajco.12170","article-title":"Economic analysis of aprepitant-containing regimen to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Hong Kong","volume":"10","author":"Chan","year":"2014","journal-title":"Asia Pac J Clin Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00520-018-4400-1","article-title":"Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study","volume":"27","author":"Chanthawong","year":"2019","journal-title":"Support Care Cancer."},{"key":"B23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2147\/CMAR.S44539","article-title":"Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK","volume":"5","author":"Humphreys","year":"2013","journal-title":"Cancer Manag Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.vhri.2012.03.002","article-title":"Aprepitant for patients receiving highly emetogenic chemotherapy: an economic analysis for Singapore","volume":"1","author":"Lopes","year":"2012","journal-title":"Value Health Reg Issues."},{"key":"B25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ejca.2006.09.019","article-title":"Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany","volume":"43","author":"Lordick","year":"2007","journal-title":"Eur J Cancer."},{"key":"B26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1524-4733.2006.00141.x","article-title":"Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy","volume":"10","author":"Moore","year":"2007","journal-title":"Value Health."},{"key":"B27","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1159\/000479032","article-title":"Clinical impact of aprepitant in patients receiving high-dose chemotherapy prior to autologous peripheral blood stem cell transplantation: a cost-effectiveness analysis","volume":"93","author":"Nakamura","year":"2017","journal-title":"Oncology."},{"key":"B28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5301\/GRHTA.5000195","article-title":"Cost-consequence analysis of aprepitant compared to standard therapy (5-HT3 + corticosteroids) for the prevention of highly emetogenic chemotherapy-induced nausea and vomit","volume":"2","author":"Ravasio","year":"2015","journal-title":"Global Regional Health Technol Assess"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e015645","DOI":"10.1136\/bmjopen-2016-015645","article-title":"Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy","volume":"7","author":"Restelli","year":"2017","journal-title":"BMJ Open"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1111\/cas.13736","article-title":"Cost-effectiveness of aprepitant in Japanese patients treated with cisplatin-containing highly emetogenic chemotherapy","volume":"109","author":"Tsukiyama","year":"2018","journal-title":"Cancer Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1002\/cncr.21343","article-title":"Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy","volume":"104","author":"Herrstedt","year":"2005","journal-title":"Cancer."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1002\/cncr.11817","article-title":"Palonosetron Study Group. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron","volume":"98","author":"Eisenberg","year":"2003","journal-title":"Cancer."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1093\/annonc\/mdg417","article-title":"Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron","volume":"14","author":"Gralla","year":"2003","journal-title":"Ann Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00520-008-0535-9","article-title":"Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy","volume":"17","author":"Grunberg","year":"2009","journal-title":"Support Care Cancer."},{"key":"B35","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00520-009-0680-9","article-title":"Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, doubleblind study","volume":"18","author":"Rapoport","year":"2010","journal-title":"Support Care Cancer."},{"key":"B36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ejca.2003.08.028","article-title":"The oral NK1 antagonist aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomized, placebo-controlled phase III clinical trials","volume":"40","author":"de Wit","year":"2004","journal-title":"Eur J Cancer."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1093\/annonc\/mdu110","article-title":"Efficacy and safety of NEPA, an oral combination of netupitant and Palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study","volume":"25","author":"Hesketh","year":"2014","journal-title":"Ann Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/annonc\/mdu101","article-title":"A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and Palonosetron, for prevention of chemotherapyinduced nausea and vomiting following moderately emetogenic chemotherapy","volume":"25","author":"Aapro","year":"2014","journal-title":"Ann Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/annonc\/mdu096","article-title":"A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and Palonosetron, for prevention of chemotherapyinduced nausea and vomiting over repeated cycles of chemotherapy","volume":"25","author":"Gralla","year":"2014","journal-title":"Ann Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1111\/j.1349-7006.2010.01689.x","article-title":"Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin","volume":"101","author":"Takahashi","year":"2010","journal-title":"Cancer Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1007\/s40265-015-0512-9","article-title":"Netupitant\/Palonosetron: a review in the prevention of chemotherapy- induced nausea and vomiting","volume":"75","author":"Keating","year":"2015","journal-title":"Drugs."},{"key":"B42","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1017\/S0266462300008953","article-title":"Principles of cost-effective resource allocation in health care organizations","volume":"6","author":"Weinstein","year":"1990","journal-title":"Int J Technol Assess Health Care."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA."},{"key":"B44","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jpainsymman.2004.04.008","article-title":"Olanzapine-induced delirium in a terminally ill cancer patient","volume":"28","author":"Morita","year":"2004","journal-title":"J Pain Symptom Manage"},{"key":"B45","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40273-015-0266-y","article-title":"Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes","volume":"33","author":"Geng","year":"2015","journal-title":"Pharmacoeconomic"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2021.660514\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T09:15:10Z","timestamp":1629882910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2021.660514\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":45,"alternative-id":["10.3389\/fpubh.2021.660514"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2021.660514","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,25]]},"article-number":"660514"}}